Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development.
about
Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseasesCommon transcriptional signatures in brain tissue from patients with HIV-associated neurocognitive disorders, Alzheimer's disease, and Multiple SclerosisHuntington's disease: underlying molecular mechanisms and emerging conceptsA chaperome subnetwork safeguards proteostasis in aging and neurodegenerative diseaseStructured Illumination Microscopy for the Investigation of Synaptic Structure and Function.New insights on the role of microglia in synaptic pruning in health and diseaseThe stress response factor daf-16/FOXO is required for multiple compound families to prolong the function of neurons with Huntington's diseaseHuntingtin-associated protein 1 interacts with breakpoint cluster region protein to regulate neuronal differentiation.Allele-selective inhibition of trinucleotide repeat genes.Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cellsA small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.Autophagy Modulation in Disease Therapy: Where Do We Stand?Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.Synaptic plasticity in neurodegenerative diseases evaluated and modulated by in vivo neurophysiological techniques.Sirtuin deacetylases in neurodegenerative diseases of aging.From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF)Investigational drugs for the management of Huntington's disease: are we there yet?Genomic medicine and risk prediction across the disease spectrum.Interactome network analysis identifies multiple caspase-6 interactors involved in the pathogenesis of HD.Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk.Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer's disease.Mitochondrial bioenergetics decay in aging: beneficial effect of melatonin.Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease
P2860
Q26776093-787736C0-6FB7-41EE-BDE7-00DF25157D4FQ27007041-F3F828C7-5DA1-4ECF-8DC9-F749C09DB623Q27026255-26FB7FD2-9C17-438F-B102-05270B201E80Q28252463-2A77A8D2-5D05-4193-A7DC-0537036B5D41Q33821458-6687C6A0-044E-4038-BA9F-54BB2EB5E986Q33821505-55F7AE3F-09A4-4443-9965-5E31C2E41FE8Q33822501-64659179-6C2A-47C0-9073-736D9ED16879Q35074377-A1CF040F-4E9C-48E8-883C-D755D9954984Q36310758-3C0C50DE-BB26-4558-BF44-D7A765EE1714Q36423519-F63E2DB0-1AD0-4DE1-820D-23DA7C9B6296Q37345118-F77CCEE8-EF4A-430E-8EE6-6AE114064D73Q37512290-0A85D703-754F-4D17-AFBB-81D9F0340441Q38022179-0EACE70A-FE90-48B5-BAF1-3E2F4C03AF0FQ38028376-34DBA2B6-56FC-4B8A-8BF7-4B91A75CF260Q38108128-B902E99B-C5BC-4277-BEA8-2ED2A82DA1F5Q38168376-1010C7CB-2616-4810-BC46-A10CDB2F1A63Q38236052-10BBFD5D-15D2-4480-AE4F-411B045C326EQ38322338-85FD9732-C353-46DC-9F44-63F14F6ADA75Q38791517-527227F5-2920-4DC0-994D-6A7C7D9E0397Q45295491-79AAF659-E307-4992-90CB-31ABFD6C6D1DQ46293996-9651EB4B-8435-4FA1-A05E-02BCA12A56FBQ47980436-3A89A94F-6ED7-4EC7-A15D-17EB16ED60F9Q57967107-ADF96CBD-3980-4C9B-ABC1-B33B34A56D86
P2860
Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Convergent pathogenic pathways ...... targets for drug development.
@en
Convergent pathogenic pathways ...... targets for drug development.
@nl
type
label
Convergent pathogenic pathways ...... targets for drug development.
@en
Convergent pathogenic pathways ...... targets for drug development.
@nl
prefLabel
Convergent pathogenic pathways ...... targets for drug development.
@en
Convergent pathogenic pathways ...... targets for drug development.
@nl
P2860
P356
P1476
Convergent pathogenic pathways ...... d targets for drug development
@en
P2093
Bibiana K Y Wong
P2860
P2888
P304
P356
10.1038/NRD3556
P577
2011-10-21T00:00:00Z